The FDA has accepted Sanofi and Regeneron’s application to expand Dupixent’s use, with a decision expected by April 2025.

Resubmission includes new pivotal data which confirm Dupixent significantly reduced itch and hive activityMore than 300,000 people in the U.S.

We tend to think of COVID-19 as a respiratory illness. But, like many viruses, COVID can also affect your skin and cause ...

Are you one of these people who loathes spending time outdoors at dusk as the weather warms and mosquitoes start biting?

Warmer weather is here and so are the mosquitoes. Here’s what happens when a mozzie bites and our body reacts.

Medically reviewed by Jurairat J. Molina, MD Acute urticaria (hives) is a common skin condition that affects up to 20% of people at some point in their lives. It can transition into chronic urticaria ...